References
- Hauser W. Epilepsy: Frequency, Causes, and Consequences. New York: Demos Press, 1990
- Kotsopoulos IA, van MT, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002;43:1402-9
- Hitiris N, Mohanraj R, Norrie J, et al. Mortality in epilepsy. Epilepsy Behav 2007;10:363-76
- Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-33
- Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure 1997;6:159-74
- Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. Drug Therapy CNS Drugs 1995;3:194-208
- National Institute for Health and Clinical Excellence. Newer drugs for epilepsy in adults. London: National Institute for Health and Clinical Excellence, 2004
- European Medicines Agency. Assessment report for Vimpat lacosamide. London: European Medicines Agency, 2008
- Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 2008;44:35-40
- Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005
- Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
- Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
- Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
- Ben-Menachem E, French J, Isojarvi J, et al. Long-term efficacy of lacosamide for partial-onset seizures: an interim evaluation of completer cohorts exposed to lacosamide for up to 36 months. Toronto: American Epilepsy Society, 2009. Available at: http://www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/lacosamide/sy/all/sb/All/id/9936 [Last accessed 17 January 2011]
- Rosenfeld W, Rosenow F, Isojarvi J, et al. Long-term safety and tolerability of lacosamide for partial-onset seizures: an interim evaluation of patients exposed to lacosamide in double-blind and open-label trials. Epilepsia 2009;50:453
- Faught E, Chung S, Husain A, et al. Long-term efficacy of lacosamide as adjunctive therapy in patients with uncontrolled POS: results from a phase III open-label extension trial. San Antonio: American Epilepsy Society, 2010. Available at: www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display?st=1%2E263&sy=2010&sb=All&id=12463 [Last accessed 18 January 2011]
- Husain A, Faught E, Chung S, et al. Long-term safety of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures: results from a phase iii open-label extension Trial. San Antonio: American Epilepsy Society, 2010. Available at: www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display?st=1%2E265&sy=2010&sb=All&id=12465 [Last accessed 18 January 2011]
- Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures -- cost utility results for Sweden. Acta Neurol Scand 2010;121:406-12
- Simoens S, Dedeken P, Benhaddi H. Cost-utility analysis of lacosamide adjunctive therapy in the treatment of partial-onset seizures in epileptic patients in Belgium. Value Health 2010;13:A393
- Soini E, Martikainen J, Vanoli A. Cost-effectiveness and budget impact modelling of lacosamide in the treatment of partial-onset seizures in Finland. Value Health 2009;12:A367
- Cramer J, De La Loge C, Borghs S, et al. Improvement in patient-reported outcomes seen in patients responding to lacosamide: pooled QOLIE-31, SSQ and PGIC data from phase II/III clinical trials. Toronto: American Academy of Neurology, 2010
- French J, Brodie MJ, Hebert D, et al. Evaluation of seizure freedom and 75% responder rates with lacosamide in subjects with partial-onset seizures in phase II/III clinical trials. Epilepsia 2009;50:112
- Gil-Nagel A, Biton V, Fountain N, et al. The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III trials. Epilepsia 2009;50:110
- O'Brien E. Data presented at the American Academy of Neurology Meeting demonstrated long-term efficacy and tolerability of Vimpat® lacosamide). Available at: www.ucb.com [Last accessed 20 January 2011]
- Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol Scand 2009;120:1-15
- Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-157